The FDA has granted Fast Track designation to BW-20805, an investigational small interfering RNA therapy for hereditary angioedema.

Disappointed investors punished Wave Life Sciences (NASDAQ: WVE), causing its shares to lose roughly half their value on Thursday after the RNA-based drug developer reported mixed early-stage interim ...

Under the terms of the merger agreement, Merck, through a subsidiary, will acquire all of the outstanding shares of Terns. As a result of the IPO, the company projects a total dilutive effect of $0.04 ...

Like tiny superheroes, small, naturally occurring segments of RNA can block multiple molecular paths that cancer cells use to ...